Olorinab (APD371)

Drug Candidate for Treatment of Pain

Olorinab (APD371) is an orally available, peripherally restricted, highly-selective, full agonist of the cannabinoid 2 (CB2) receptor. Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, including visceral pain. This compound, through its selectivity for CB2, is designed to provide pain relief without psychotropic effects and without the potential for dependence or abuse.


We have initiated a randomized, open-label and parallel Phase 2 clinical trial to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of Olorinab.

Drug Candidate Disease Area Target Status Retained Rights
Olorinab (APD371) Pain CB2 Agonist Phase 2 Ongoing Worldwide

Drug Candidate Olorinab (APD371)
Disease Area Pain
Target CB2 Agonist
Status Phase 2 Ongoing
Retained Rights Worldwide

Olorinab (APD371) has not been approved by the US Food and Drug Administration or any other regulatory agency.